2014年7月15日 星期二

High blood pressure may protect elderly against dementia

from: http://www.health24.com/News/High-blood-pressure-may-protect-elderly-against-dementia-20140715



High blood pressure may protect elderly against dementia

In the extreme elderly those with the highest blood pressure were the least likely to have dementia, according to new research.


New research suggests high blood pressure may not be all bad. Elevated levels might help to stave off mental decline among the extreme elderly, the study suggests.
The finding follows a decade spent tracking high blood pressure and dementia among 625 men and women aged 90 and up.
Those with the highest blood pressure levels were the least likely to have dementia, the researchers found. But that doesn't mean older people shouldn't try to control elevated blood pressure, they said.

Read: Hypertension in the elderly

High blood pressure must still be treated


"On the basis of this work we are absolutely not recommending that high blood pressure not be treated among the elderly," said study co-author Maria Corrada, an associate adjunct professor in the department of neurology at the University of California, Irvine.
"What we are saying is that from observing a group of very old people we now have some evidence that developing high blood pressure at a late age may be helpful in terms of maintaining intact thinking abilities," she said.
The reason behind this association isn't clear, Corrada said. "It could be that high blood pressure improves the blood flow to their brain... But we don't know. It will certainly require more study to better understand the mechanism behind this."
The study didn't prove that high blood pressure leads to improved mental acuity among the very old, it just found a link between the two.

Read: Improved treatment for high blood pressure
Corrada and her colleagues are scheduled to discuss their findings this week in Copenhagen, Denmark at an international meeting of the Alzheimer's Association. Research presented at meetings is considered preliminary until published in a peer-reviewed medical journal.
Battery of tests

For the study, the study authors focused on men and women aged 90 to 103 – the "oldest old."
Almost seven in 10 participants were women, and at the start of the study none had dementia. All underwent an initial battery of mental health and neurological testing, as well as blood pressure assessments.
Then, for up to 10 years, all participants were re-evaluated every six months.
Overall, 259 were diagnosed with dementia. And nearly three-quarters took some form of medication to control high blood pressure, which is linked to heart disease and stroke.

Read: A healthy heart may keep your mind sharp

Even lower dementia risk


The research team found that those who had developed high blood pressure during their 80s faced a lower risk of developing dementia than those with normal blood pressure. And participants first diagnosed with high blood pressure during their 90s had an even lower dementia risk.
Even those whose blood pressure was slightly elevated – called "pre-hypertension" – had a lower risk for dementia than those with normal blood pressure, the study found.
The absolute lowest dementia risk was seen among those whose high blood pressure was the most advanced. The association held whether or not people took medication for their high blood pressure.

Read: Seniors need less blood pressure medication

Conclusion


This led the research team to conclude that high blood pressure seems to be associated with a lower risk for dementia among the extreme elderly. Moreover, the worse a person's blood pressure status is, the better their thinking capacities, the researchers said.
"Now it should be said that people who survive to age 90 and above are, by definition, very different than people who survive to their 70s or 80s," said Corrada. "Obviously, they didn't have stroke or heart disease that took their lives. Or maybe they didn't have it at all. And more specifically, these may be people who have developed high blood pressure now, but did not struggle with it throughout their life."

Catherine Roe, an assistant professor of neurology at Washington University School of Medicine in St. Louis, said the findings seem to "fit with what we know about high blood pressure".

Read: Brain structure influences thinking
"High blood pressure during middle-age is a risk factor for later development of dementia," Roe said. "That's pretty clear from past research. But the study results have been mixed on whether high blood pressure for people in their 60s and 70s is related to cognition problems or not." Cognition refers to thinking and memory.
It appears that high blood pressure becomes less of a risk factor for mental decline in old age, Roe added. However, "high blood pressure is probably still bad for a lot of other reasons," she said.
Perhaps people who live to very advanced ages have a kind of "super health" that helps them withstand the impact of high blood pressure, she suggested. 

2014年7月13日 星期日

Blowing mind games up in smoke


Blowing mind games up in smoke
REPRESENTATION PIC
HEALING THROUGH DRUGS?

Many psychiatric patients as young as 14 years, have taken to self-medication with mind-altering substances to gain control over medical disorders

Ruhi, a resident of Vashi, was hit by an overpowering libido when she was barely 13-and-half years old. Not only did she take to unprotected sex with strangers, she even forced her 11-year-old brother into oral sex. She also had a sex clip made of herself in the act and let it go viral.

By 15, not knowing how to deal with her irrepressible nymphomaniac tendencies, she turned to methamphetamine and cocaine. Substance abuse gave her control over her personality disorder, but the minor's selfmedication brought her to the doorstep of a Pune-based NGO, a couple of weeks ago, to cure her of her new addiction.

It is a given that many junkies take to drugs to fight depression or other psychological issues. These were mostly people who have not recognised their state as a clinical condition but just drifted to substance abuse. But lately, de-addiction centres are noting that some cases, alarmingly many of them minors, coming to them are known clinical psychiatric patients who have turned to narcotics as a self-medication initiative.

Twenty-year-old Tejas, from Pune, in his final year of graduation in commerce, was diagnosed with schizophrenia. He had spiritual hallucinations about the deity Ram, perched atop a mountain. He was prescribed anti-depressants. But struggling with drug adherence, Tejas' condition worsened. Putting away his prescription, he sought solace in marijuana. The cannabis rid him of the apparition that haunted him, but also hooked him into a dependency he could do without.

Waking up to his conditions, his parents brought him to Practical Life Skills De-addiction and Rehabilitation Centre, Pashan. Pune's sixteen-year-old Aditya, in his junior college studying commerce, was on anti-depressants to cope with his clinical condition. But the medication was not helping, when his friends introduced him to the joy of sniffing glue. Aditya's depression drove him to masochistic behaviour and he often nicked or inflicted other physical abuse on himself. The glue came to his rescue.

After eight months of sniffing glue, his failing health caught his parents' attention, who dragged him to the deaddiction centre last month. "In past couple of months, we have admitted about six such cases, all aged between 15 and 24, who have indulged in self-medication with mind altering or mood changing substances.

More than alcohol, children as young as 15-16 are trying to take care of their psychiatric inconsistencies with substance abuse," noted Indrajit Deshmukh, project head at Practical Skills. "Our in-patient department (IPD) earlier dealt largely with people above 40 years in age. However, in the past eight to 10 months we are seeing a stream of young patients mostly in the age bracket of 14 to 20 years.

Many of them took to substances in the hope that they would be cured of their mental distress." said Dr Nitin Dalaya, director at the Nityanand Rehabilitation Centre, a 300 bedded facility at Katraj. Most of his patients come from Maharashtra, Madhya Pradesh, Gujarat and Goa. "Some of these kids have even graduated to multiple/poly-drug abuse.

The new thing going around is a combination of Vicks Action 500 along with Nitrazepam, Nitravet and Spazmo Proxyvon, These drugs taken in combination, yield a high far above what comes from cocaine or marijuana. Their physical impact is also equally exponential and prolonged use can use can lead to renal and liver failure or gastric ulcers.

We had two teenagers from Mumbai who had come with renal failures within four months of doing this permutation," Dr Dalaya said. "The age of people with diagnosed clinical psychiatric condition taking to self-medication in this manner, have certainly come down.

Cannabis is the preferred substance for them. Since at Muktanagan we don't admit kids of that low age we cannot give the details, but yes, in the last seven-eight months we were approached by many cases aged between 15 and 18, who we redirected to centres that do pediatric admissions," said Sanjay Bhagat, project co-ordinator, Regional Resource and Training Center West Zone 1, and coordinator at Muktangan De-addiction and Rehabilitation Centre. He added that the rising numbers indicate an urgent need to educate children on the adverse effect of such abuse.

Apart from the de-addiction centres, even psychiatrists are aware of this rising number of patients switching to illegal stimulants as selfmedication. "Five years ago, I would barely get a teenager patient who had taken to narcotics despite being a clinically diagnosed psychiatric patient. In the last six months, however, I have seen over 20 such cases.

All the cases were aged between 15 and 25 years,"said Dr Amod Borkar, a psychiatrist with private practice at Karve Nagar. Dr Ulhas Luktuke, life fellow at the International Council of Sex Education and Parenthood and life fellow at Indian Psychiatrists Association, too acknowledging the increasing trend of self-medication with drugs, pointed out, "Easy accessibility to the drugs and the absence of watchful eyes in a nuclear family is engendering this situation.

More than medication, what is required here is sensitisation of parents through workshops, so they have a better understanding of their growing children and provide the necessary support to them."

►►► We are seeing a stream of young patients between 14 to 20 years who took to substances to be cured of mental distress

- DR NITIN DALAYA, Director, Nityanand Rehabilitation Centre

2014年7月12日 星期六

Report: Patient-Generated Data Will Help Shape Future of Medicine

from: http://www.ihealthbeat.org/articles/2014/7/11/report-patientgenerated-data-will-help-shape-future-of-medicine

Report: Patient-Generated Data Will Help Shape Future of Medicine


Patient-generated data will play a critical role in the future of medicine and will help shape the evidence base that physicians, patients and policymakers use to improve the quality of care, according to an analysis published in Health Affairs, Modern Healthcare's "Vital Signs" reports (Conn, "Vital Signs," Modern Healthcare, 7/9).

Report Details

For the analysis, Duke University researchers examined the effect of collecting real-world data directly from patients as opposed to gathering such data through randomized controlled trials (Dvorak, FierceHealthIT, 7/10).
The authors defined patient-generated data as patient-reported outcomes.

Report Findings

The report found that patient-generated data will be "critical to developing the evidence base that informs decisions made by patients, providers and policymakers in pursuit of high-value medical care."
Specifically, the researchers wrote that the "key to high-quality, patient-generated data is to have immediate and actionable data" that allows patients to realize the importance of the data for research, as well as their personal care.
They added, "The easier it is for patients and clinicians to navigate [personal data], the more relevant that information will be to patient care, the more invested patients and clinics will be in contributing high-quality data, and the better the data in the big-data ecosystem will be" ("Vital Signs," Modern Healthcare, 7/9).
The researchers noted that physicians are increasingly using data captured directly from patients to help understand patients' health outcomes. They added that the ability to capture such data is growing in part because of the widespread adoption and use of electronic health records and monitoring devices.
However, they noted that full EHR implementation and interoperability have yet to be achieved (FierceHealthIT, 7/10).
In the meantime, the researchers recommended that physicians take simple steps to better familiarize patients the data collection efforts, such as by physicians telling a patient that they have seen their "symptom report" ("Vital Signs," Modern Healthcare, 7/9).

PTCB Math Review: Pediatric Doses: Clark's Rule

from:  https://www.youtube.com/watch?v=iYWtfblf4PE




I like making these videos and it gives me great satisfaction to help people study for the exam with my videos.I would greatly appreciate anything you are inspired to give!! Thank you!Here is the link to donate to my YouTube videos: https://www.paypal.com/cgi-bin/webscr...
ptcb_tutor@yahoo.com
PTCB Math Review will help you understand and memorize the formulas you need in order to pass the exam.
**These Tutorials are only for the purpose of studying for the PTCB Exams. In a professional setting or for compounding actual solutions, check with your supervising pharmacist.

2014年7月7日 星期一

Arizona heightens oversight of medications for foster children

from: http://tucson.com/news/local/arizona-heightens-oversight-of-medications-for-foster-children/article_d4ee1bb3-a7d3-55ac-b7a6-ddc410f3064a.html

July 06, 2014 12:00 am • By Emily Bregel A study based on 2008 prescription claims found that 11 percent of Arizona foster kids — 1,681 children — took at least one psychotropic drug, like anti-depressants, anti-psychotics and stimulants such as Ritalin for attention-deficit disorders. More than 1 in 4 children ages 6 to 12 were taking the drugs, compared with one in 20 non-foster children that age. Still, Arizona's overall rate was lower than rates in five U.S. states studied in a U.S. Government Accountability Office report, where 19 percent to nearly 40 percent of foster youth in 2008 were on at least one psychotropic drug. "It is indeed concerning," said Dr. Kathy SmithKathy Smith, director of child and adolescent psychiatry at the University of Arizona."What’s causing that, is the question. Is it because we have people who don’t have enough expertise prescribing medication? Is it because of changes in caregivers? Is it because these kids are really complicated?" Raised on Tucson’s east side by an abusive parent, Angela Luna entered foster care at age 14. After being diagnosed with bipolar disorder, she was put on antidepressants and anti-anxiety medications and stayed on them for seven years. But she says her emotional problems were related to her childhood trauma, not mental illness. The medications numbed her pain and anger, she says, and prevented her from learning how to deal with her emotions — or even knowing how she felt. “I constantly felt stoned and high,” says Luna, now 28, who has since been diagnosed with post-traumatic stress disorder. “You’re never given the chance to properly grow. ... Therapists ask, ‘How’s your medication?’ Not ‘How are you?’” Arizona foster children were 4.4 times more likely than nonfoster children on Medicaid to be prescribed powerful psychotropic drugs, a report based on 2008 data found. Arizona hasn’t updated that report, but the number of foster kids on psychotropic drugs likely has grown along with the state’s foster-care population: Between March 2008 and March 2014, the number of Arizona children in foster care soared by 62 percent from 9,721 to 15,750. Child-welfare advocates attribute the growth to deepening poverty leading to more cases of neglect. When used appropriately, psychotropic drugs — which affect mood, thought or behavior — can be lifesaving, experts say. But some child-welfare advocates say the drugs can be prescribed more for the convenience of overwhelmed caregivers than for the benefit of the child. “I see youth that are so overly medicated that they’re literally drooling,” said Christa Drake, former executive director of In My Shoes, a mentorship program for foster youth. “Sometimes it’s like, ‘Let’s just medicate him and subdue him so we don’t have to deal with the behavior.’” This year the state implemented new oversight and heightened reporting requirements regarding prescriptions for foster kids, said Steven Dingle, chief medical officer of the Arizona Division of Behavioral Health. As of January, “regional behavioral health authorities” — organizations that coordinate behavioral health care for foster kids — must regularly submit data on medication utilization rates among foster kids. The behavioral health authorities will also monitor the prescribing habits of doctors in their region and identify outliers. In addition, doctors must now get authorization — attesting they first tried psychosocial interventions like therapy — before prescribing the following: •antipsychotic or ADHD medications for children under age 6; •any psychotropic drug at a dosage level exceeding FDA recommendations; •more than one antipsychotic or antidepressant simultaneously. The state has also formed the Arizona Psychotropic Monitoring Oversight Team, a partnership between the Department of Child Safety, AHCCCS and the Division of Behavioral Health Services focused on ensuring appropriate prescribing, Dingle said. The team plans to replicate the study on psychotropic prescriptions among 2008 foster children with more recent data, likely within the next six months, he said. Normal behaviors Despite the new reporting requirements, some worry medication use could increase as Arizona’s child welfare system is stretched. Last November, the Arizona Department of Economic Security admitted that its Child Protective Service division failed to investigate more than 6,500 reports of abuse or neglect, in part due to sky-high caseloads for CPS caseworkers. CPS oversight was taken from DES and given to the newly created Department of Child Safety in May. Heavy caseloads leave caseworkers, caregivers and doctors with less time to concentrate on each child’s medication regimen. A foster family shortage also means more children are in group homes, with less individualized attention, increasing the risk of fragmented oversight of their care. “The system remains ripe for medication misuse or overuse,” says Sen. David Bradley, D-Tucson, who worked in child welfare for 20 years. Finding solutions other than medication takes resources, time and patience, said Drake, formerly of In My Shoes. Foster children need stability and a safe space to explore and express their emotions, she said. Instead, lots of kids get a diagnosis of conditions like “oppositional defiance disorder” when they act out, she said. That diagnosis can sometimes medicalize normal behavior, she said. “Most people would be upset if they were ripped away from their families and sent to live in a group home,” she said. “A lot of our youth are acting appropriately in their surroundings.” Foster kids with complex needs are often bounced between therapeutic and regular foster homes as their behavior stabilizes, then deteriorates again, said Sarah Huntoon, foster program director for Intermountain Centers for Human Development, which trains and licenses therapeutic foster homes. The more transitions, the more instability for the foster child — and the less likely he is to have a familiar caregiver who will notice and report concerns about medications. “Consistency of care is an issue,” she said. Trauma is a given Experts say it makes sense that kids in foster care have a higher rate of psychotropic-drug use than other kids. Between 60 and 80 percent of foster youth have at least one psychiatric diagnosis or developmental disability, compared with 15 to 20 percent of the general population, said Dr. Sandy Stein, associate medical director of Community Partnership of Southern Arizona, the Regional Behavioral Health Authority for Pima County. The authority coordinates and manages behavioral health care for children in the child welfare system. Some of those diagnoses in foster children are related to lack of prenatal care, to parental substance abuse or to a family history of mental illness, Stein said. Lengthy stays in foster care, or transitions between foster families and group homes, can add to a child’s sense of instability. “These kids have been traumatized,” says Susie Huhn, executive director of Casa de los Niños, a social-service and foster-care agency in Tucson. “The very fact that they’re in the foster care system means they’ve been exposed to toxic stress and traumatic events — so why wouldn’t we expect they’ll have more social or emotional issues?” But some worry about questionable prescribing practices. Among the 2008 psychotropic drug report’s findings: •Foster kids were nine times more likely than nonfoster children to be prescribed five psychotropic medications at one time. Almost 800 children, or 5.4 percent of the foster population, were taking two or more drugs. Only limited evidence supports the use of even two psychotropic drug in children, and no evidence supports children — or even adults — taking five at once, according to the U.S. Government Accountability Office. •Arizona foster children ages 5 and younger were 5.5 times more likely than nonfoster children to be prescribed at least one psychotropic medication. That year, 225 Arizona foster children 5 and younger were prescribed the drugs. •The state’s foster kids were 7.4 times as likely to be prescribed the drugs in doses exceeding the maximum recommendation for their age group. •Fifty-five foster children ages 1 and younger got a psychotropic prescription in 2008, though the report notes some drugs could have been prescribed to treat other conditions. The drugs can have serious side effects for infants, and the GAO points out that there is no established use for these drugs to treat mental-health conditions in infants. Long-term harm Even if kids improve with medication, powerful psychotropics may do a lifetime of harm. Common side effects include paranoia, weight gain, extreme fatigue and reduced bone density. Little research has been done on long-term impacts on brain development in children. And unlike in adults, side effects like weight gain can become permanent for children, even after they’re taken off the medication. Proper diagnosis is often a challenge. Post-traumatic stress disorder can look a lot like ADHD, and the treatments for each are different, said Laurel Rettle, critical-care coordination administrator for Cenpatico, one of four Regional Behavioral Health Authorities in Arizona. Although medications can help those who suffer from PTSD in the short term, long-term use of stimulants — like ADHD treatments — will not. PTSD “is not, in and of itself, a serious mental illness,” she said. “These children are dealing with things they never should have to deal with. You can compare it to children of war.” Geara Patten has been a therapeutic foster mom since 1998. Most of her foster children came to her already on medications, she said, and many stayed on them until they aged out of the system. She believes psychotropic medications were used generally only when necessary and helped many of her foster kids get through a difficult time. Still, most of her foster kids ended up stopping their meds as soon as they gained independence, she said, and they seemed to thrive without the drugs. “They’re at a calmer place,” she said. “I imagine 90 to 95 percent of them take themselves off the medicine.” “Ass Bouncing between foster homes, group homes and behavioral-health facilities for foster youth, Luna learned to accept that the drugs were a necessary part of her life. “You take the meds and shut up and deal with it, or you get in trouble,” she recalled of her time in a group home. “No one’s there to tell you that we all struggle. It makes you hopeless.” A foster-care mentor was the first person to suggest her emotions and anger were understandable, and that she wasn’t destined to always need medication. Drake, of In My Shoes, encouraged Luna to question her medication protocol. “Christa saved my life,” she said. “Christa told me, ‘You have a right to know about your medicine.’” Starting this month, CPSA is formalizing an “assent” process for foster children under 18 to sign off on their treatment plan, said Stein of Community Partnership of Southern Arizona. “Assent” is not legally binding, as the child’s caregiver has the final say on treatment, but the process will ensure children understand their diagnosis, treatment options and the goals of their medications, she said. “It’s absolutely essential to engage kids in their overall health-care treatments,” she said. Luna got off her medications at age 21 and earned her GED. She put herself through cosmetology school and as a hairstylist, client after client praised strengths she never realized she possessed: her compassion and listening skills. Now in her work as a mentor to foster youth, Luna says she sees children on four or five different psychotropic medications at a time. Some may have serious mental illnesses and require medication, but she thinks many of them just need understanding. Giving foster kids the emotional tools to cope with their trauma will have a far more positive effect on their lives, she said. “You have to cherish all your broken pieces,” she says, “because it makes a beautiful mural.”

2014年7月2日 星期三

Innovative drug discovery speeds new treatments to patients .


Dr. Mark Fishman, president of Novartis Institutes of BioMedical Research (NIBR), talks about the Novartis commitment to science-based innovation and the search for new medicines for unmet patient needs.

2014年7月1日 星期二

Student designs new syringe to help elderly take medicines


A design student has invented a new type of oral syringe to make loading and administrating medications easier, especially for older patients.

Design student Rhian Bache’s final-year project at London’s Brunel University has been selected for the prestigious Made in Brunel Exhibition on the South Bank.
Ms Bache, 22, realised that with an increasingly elderly population often taking many different medicines, many of which are only available in liquid form, self-administering accurate doses using a needle-less syringe was a real challenge for many patients.
Rhian Bache
Rhian Bache
She said: “Self-loading and administrating medications with existing oral syringes is extremely difficult to do accurately, especially for those suffering from poor coordination, or hand weakness.
“There are two problems, you can’t easily gauge what dose is going in and have to turn the bottle upside-down to fill the syringe,” she said.
Ms Bache’s prototype gadget solves both, and can be used by left-handed and right-handed patients.
The main concept is to simplify use by holding the syringe horizontally using an oral accessory. By allowing the user to keep the syringe flat, they are free to concentrate on the rate of medication flow rather than keeping the syringe stationary within the oral cavity.
From this initial concept, Ms Bache developed a full range of accessories. A new bottle adapter removes the need to invert and elevate the medicine bottle, while a handle accessory decreases pressure on the user’s palm and fingers.
The device is now going into further development with hospital doctors and nurses.
Visit the Made in Brunel website for more information on the prototype device.
Brunel
Rhian Bache’s new oral syringe and accessories

2014年6月29日 星期日

Northwestern Medicine Researchers Discover New Way To Prevent Some Strokes

from: http://www.redorbit.com/news/health/1113180718/northwestern-medicine-researchers-discover-new-way-to-prevent-some-strokes-2/

 

Northwestern Medicine Researchers Discover New Way To Prevent Some Strokes

June 28, 2014

      21
Larry Ambrose was diagnosed as having a stroke a few days after he woke up one night, wandered into his kitchen and couldn’t read the time on his microwave. Ambrose, like 25 percent of all stroke patients, experienced a cryptogenic ischemic stroke, meaning physicians were unable to determine a cause.
For these patients, physicians believe atrial fibrillation, the most common type of arrhythmia (abnormal heart beat), may occur without the patient’s knowledge, causing the stroke. During atrial fibrillation, the heart’s upper chambers, or atria, quiver rather than beat; this allows blood to stay in the chamber and potentially cause a clot. If the clot travels from the heart and reaches the brain, a stroke is imminent.
To research this connection, Northwestern Medicine® physician researchers from cardiology and neurology teamed up to conduct a four-year trial which enrolled 441 people across 55 centers. Half the patients received a small implantable cardiac monitor that continuously records the rhythm of the heart and lets the physician know over the internet when an abnormal rhythm has occurred Northwestern Memorial Hospital was the lead site in North America for the trial.
The results found that by using this device, 30 percent of people with cryptogenic stroke have atrial fibrillation detected within 3 years, which is the battery life of the device.. In those patients who received standard techniques for follow up, physicians only found atrial fibrillation in about 3 percent of these patients. Because of these results, the 30 percent were all switched to blood thinners which should protect them better from having another stroke.
The research findings were published in a June 26, 2014 article in the New England of Medicine. Because cryptogenic strokes are common, these findings could help hundreds of thousands of people every year. More than 750,000 people suffer a stroke in the United States every year and about one third of those are cryptogenic strokes.
“Having a stroke really rattles your foundations,” said Richard Bernstein, MD, director of the Northwestern Medicine Stroke Program and Telestroke. “Being told by your doctor that they have no idea why you had it and that they are just guessing at the best medication to prevent another one is even worse. With this clinical trial, we eliminated that second problem – not knowing the cause – in about a third of those patients.”
The patients monitored were part of a study called CRYSTAL AF (Study of Continuous Cardiac Monitoring to Assess Atrial Fibrillation after Cryptogenic Stroke). Bernstein, who is also a professor of neurology at Northwestern University Feinberg School of Medicine and his co-investigator Rod Passman, MD, director for the Center for Atrial Fibrillation at the Bluhm Cardiovascular Institute, are on the international steering committee for the CRYSTAL AF trial.
When atrial fibrillation is detected in a patient following stroke, anticoagulant therapy is recommended for secondary stroke prevention. While anticoagulant therapy can be successful in preventing future stroke, physicians do not use it proactively unless atrial fibrillation has been detected because of potential risk from the medication and complexity of the treatment. The continuous monitoring device captured and automatically stored any abnormal ECG activity. Passman and his team then reviewed and analyzed the remotely-transmitted data. After the participants were implanted, they are followed at one month and every six months thereafter for three years. The control group received standard of care optimal medical treatment and followed up at the same intervals.
“We found using a tiny implantable device to find atrial fibrillation is much better than the usual tests we previously used,” said Passman, who is also a professor of medicine and preventive medicine at the Feinberg School of Medicine. “This is critical because finding atrial fibrillation in patients with stroke of unknown cause is important because once we find it, we put the patients on blood thinners and they are much more effective than the aspirin-like drugs they would otherwise be on.”
Ambrose was identified by Bernstein as a cryptogenic stroke patient and was the first subject implanted by Passman as part of the CRYSTAL AF trial. While atrial fibrillation was not detected in Ambrose, he said simply having the device implanted and knowing that his heart rhythm was normal was a comfort.
“I knew people were monitoring me and I was helping doctors figure out a way to end the worry of having a second stroke for other patients like me,” said Ambrose, a Chicago resident. “Otherwise, I would have just gone home and been very nervous it was going to happen again.”

Read more at http://www.redorbit.com/news/health/1113180718/northwestern-medicine-researchers-discover-new-way-to-prevent-some-strokes-2/#GQ3cBotwx6jSm5T4.99

2014年6月20日 星期五

Pharmacology update: 2014 drug trends


NASHVILLE -- More orphan drugs approved in recent years are filling the need for treating rare disease and medical conditions, according to a presenter at the the American Association of Nurse Practitioners 2014 meeting.
Alan Agins, PhD, who gave a pharmacologic overview of drug approvals since 2012, noted a growing trend among pharmaceutical companies.


“I think what we're going to see for the next [two decades] is more specialty drugs,” Agins told Clinical Advisor. “Overall for the last 15 years, the number of drugs approved has gone down, partly because we've pretty much filled out our dance cards on chronic diseases.”
There were 27 first-of-a-kind drugs approved by the FDA in 2013 compared to 39 approvals just the year before. About a third of those approvals were indicated for the treatment of rare conditions and diseases.
Of note, afflicted patients with several conditions would benefit the most from recent approvals, Agins said.
Patients with chronic obstructive pulmonary disease (COPD) can now benefit from once-daily inhalers such as fluticasone and vilanterol (Breo Ellipta). Ease of use and convenience allow for better adherence in the patient population.
Patients with type 2 diabetes can take once-weekly GLP-1 agonists, enabling patients to avoid the hassle of maintaining the pharmacokinetics of the drug with once- or twice-daily dosing. Drugs such as exenatide, although expensive, have better efficacy and fewer side effects.
Newer oral anticoagulants such as dabigitran give patients more flexibility when it comes to diet and lifestyle modifications compared to warfarin. In studies, these medications were associated with lower rates of hemorrhage compared to warfarin, showed no interactions with diet/lifestyle, and did not need to be monitored.
Agins also warned about several unmet needs in drug development, most damagingly from growing drug resistance in antibiotics and the lack of new antibiotic classes.
“The newest class of antibiotics for primary care providers is now 32 years old,” he said about fluoroquinolones. “It's so much so [a problem] that the government actually spent about $200 million last year to hire one of the pharmaceutical companies to develop new antibiotics.”
Alzheimer disease is another condition with an increasing lack of drug treatment options. “Since 1998, over 104 drugs have entered clinical trials and have all failed in terms of AD,” Agins said. “We have an idea of what causes the disease but we're still not definitive, and we certainly don't have any drugs out there on the near horizon.”
Agins is hopeful that in the next 20 years, we will be making the switch from simply managing diseases with drugs to curing them outright.
“But it's going to take some biotechnology and microbiology,” he said. “We're treating symptoms of hypertension and cholesterol and all those other things now, eventually we're going to cure those diseases or prevent them totally.”

Reference

  1. Agins AP. #14.3.039. “New Drugs in the Arsenal in Primary Care.” Presented at: AANP 2014. June 17-22; Nashville, Tenn.

Pharmacology update: 2014 drug trends

from: http://www.clinicaladvisor.com/pharmacology-update-2014-drug-trends/article/356753/



 

Pharmacology update: 2014 drug trends

Alan Agins, PhD, who gave a pharmacologic overview of drug approvals since 2012, noted a growing trend among pharmaceutical companies.

“I think what we're going to see for the next [two decades] is more specialty drugs,” Agins told Clinical Advisor. “Overall for the last 15 years, the number of drugs approved has gone down, partly because we've pretty much filled out our dance cards on chronic diseases.”
There were 27 first-of-a-kind drugs approved by the FDA in 2013 compared to 39 approvals just the year before. About a third of those approvals were indicated for the treatment of rare conditions and diseases.
Of note, afflicted patients with several conditions would benefit the most from recent approvals, Agins said.
Patients with chronic obstructive pulmonary disease (COPD) can now benefit from once-daily inhalers such as fluticasone and vilanterol (Breo Ellipta). Ease of use and convenience allow for better adherence in the patient population.
Patients with type 2 diabetes can take once-weekly GLP-1 agonists, enabling patients to avoid the hassle of maintaining the pharmacokinetics of the drug with once- or twice-daily dosing. Drugs such as exenatide, although expensive, have better efficacy and fewer side effects.
Newer oral anticoagulants such as dabigitran give patients more flexibility when it comes to diet and lifestyle modifications compared to warfarin. In studies, these medications were associated with lower rates of hemorrhage compared to warfarin, showed no interactions with diet/lifestyle, and did not need to be monitored.
Agins also warned about several unmet needs in drug development, most damagingly from growing drug resistance in antibiotics and the lack of new antibiotic classes.
“The newest class of antibiotics for primary care providers is now 32 years old,” he said about fluoroquinolones. “It's so much so [a problem] that the government actually spent about $200 million last year to hire one of the pharmaceutical companies to develop new antibiotics.”
Alzheimer disease is another condition with an increasing lack of drug treatment options. “Since 1998, over 104 drugs have entered clinical trials and have all failed in terms of AD,” Agins said. “We have an idea of what causes the disease but we're still not definitive, and we certainly don't have any drugs out there on the near horizon.”
Agins is hopeful that in the next 20 years, we will be making the switch from simply managing diseases with drugs to curing them outright.
“But it's going to take some biotechnology and microbiology,” he said. “We're treating symptoms of hypertension and cholesterol and all those other things now, eventually we're going to cure those diseases or prevent them totally.”

2014年6月12日 星期四

Needle-Free Blood Sugar Testing

 

Find out how new diabetes technology called continuous glucose monitoring could make finger pricks a thing of the past.

Medically reviewed by Pat F. Bass III, MD, MPH

Constant finger pricks with needles is a task that most people with diabetes accept as part of life. Blood tests check blood sugar or glucose, and regular glucose monitor measurements are essential for making decisions about food, exercise, and medications. In the near future, however, needle-free blood sugar testing may replace the finger prick through a technology called continuous glucose monitoring (CGM).

How? Needle-free blood sugar testing devices replace the finger prick part of blood sugar testing with a tiny sensor that is implanted under the skin. The sensor measures glucose levels in the fluid beneath the skin, which corresponds closely to blood sugar levels. Instead of a needle prick several times a day, the CGM system sensor stays in place for several days.
"A transmitter continually picks up readings from the sensor and sends them to a monitor that will set off an alarm if blood sugar is too high or too low," says Howard Wolpert, MD, who established and directs the Insulin Pump & Continuous Glucose Monitoring Programs at the Joslin Diabetes Center in Boston. Dr. Wolpert is also the lead researcher on several CGM studies.

CGM Diabetes Technology

"What we have now is just the first generation of continuous blood sugar testing technology," says Wolpert, who notes that needle-free blood sugar testing is not widely available yet. "In the future we will have systems that are more accurate and easier to use," he says.
The sensor and transmitter are water-resistant, so patients can bathe or shower with them in place. The glucose information is sent by radio waves to a monitor sized to be handheld. The Joslin CGM program has already trained more than 570 adults with type 1 diabetes to use CGM.
CGM systems that are now available and approved by the U.S. Food and Drug Administration (FDA) include devices made by Abbott, DexCom, and Medtronic. A new system that replaces the implanted sensor with a sensor that works through the skin surface, called Symphony tCGM (made by Echo Therapeutics), is working its way through FDA approval.
In recent clinical studies at Thomas Jefferson University Hospital in Philadelphia, the Symphony tCGM system was able to give clinically accurate blood sugar readings 98.9 percent of the time in surgery patients.

The Pros and Cons of Needle-Free Blood Sugar Testing

Current CGM systems offer some big improvements in diabetic technology:
  • A continuous display of glucose levels is available for five to seven days before the sensor needs to be changed.
  • The information can be downloaded to a personal computer. Long-term trends appear in graph form and can be correlated with diet and activity.
  • Readings on the handheld receiver can be programmed to appear every few minutes.
  • An alarm system warns of high or low blood sugar levels.
"We still have a ways to go before CGM replaces the traditional finger stick," Wolpert notes. "The systems still need to be refined. They are not as accurate as they need to be." Drawbacks include:
  • CGM measures glucose in fluid beneath the skin and is still not as accurate as actual blood sugar testing.
  • Before an insulin dose can be changed, a CGM reading should still be verified by a blood sugar reading.
  • Learning how to use the system can be challenging for some people.
  • The system is expensive and may not be covered by insurance.
Researchers are also working on combining CGM systems with a computer that will respond to continuous glucose readings and trigger an insulin pump that will automatically dispense the right amount of insulin. This diabetes technology is called an artificial pancreas. "We are still several years away from replacing the finger prick and the glucose monitor, but diabetes research is moving forward all the time," says Wolpert.
For anyone with diabetes, diabetes technology could change the way you test your blood sugar in the not-too-distant future. In the meantime, using a finger prick and a glucose meter is still the best way to keep your diabetes under control and prevent complications.